GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Aidea Pharmaceutical Co Ltd (SHSE:688488) » Definitions » Debt-to-EBITDA

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Debt-to-EBITDA : -6.54 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Jiangsu Aidea Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jiangsu Aidea Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥386.5 Mil. Jiangsu Aidea Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥96.8 Mil. Jiangsu Aidea Pharmaceutical Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ¥-73.9 Mil. Jiangsu Aidea Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -6.54.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:688488' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.71   Med: -0.23   Max: 3.45
Current: -4.18

During the past 8 years, the highest Debt-to-EBITDA Ratio of Jiangsu Aidea Pharmaceutical Co was 3.45. The lowest was -11.71. And the median was -0.23.

SHSE:688488's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs SHSE:688488: -4.18

Jiangsu Aidea Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Aidea Pharmaceutical Co Debt-to-EBITDA Chart

Jiangsu Aidea Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 2.04 0.01 -0.47 -2.08 -11.71

Jiangsu Aidea Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.17 -2.14 -8.71 -2.79 -6.54

Competitive Comparison of Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA

For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA falls into.



Jiangsu Aidea Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(339.405 + 72.895) / -35.219
=-11.71

Jiangsu Aidea Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(386.548 + 96.825) / -73.896
=-6.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Jiangsu Aidea Pharmaceutical Co  (SHSE:688488) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Jiangsu Aidea Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jiangsu Aidea Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Aidea Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 2 Liuzhuang Road, Hanjiang District, Jiangsu Province, Yangzhou, CHN, 225008
Jiangsu Aidea Pharmaceutical Co Ltd produces and sells human-derived protein products, and also develops some generic drug businesses and distributes Abbott's HIV diagnostic equipment and reagents. The company focuses on development of new chemical entities of anti-tumor, anti-virus and cardiovascular areas, among which two NCE drugs for the treatment of Cancer and AIDS have been approved.
Executives
Wang Jun Directors, senior managers
Fu He Liang Director, core technical staff
Zhang Jie Directors, senior managers
Yuan Yu Core technical personnel
Su Gu Fang Core technical personnel
Zhang Ji Bing Core technical personnel
Wang Guang Rong Directors, senior managers
Yu Ke Directors, senior managers

Jiangsu Aidea Pharmaceutical Co Headlines

No Headlines